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Although pancreatic enzyme replacement therapy (PERT) is effective in the alleviation 
of pancreatic exocrine insufficiency (PEI)-related symptoms in patients with chronic 
pancreatitis, its mechanism of action is poorly understood. Recent studies suggest that 
the intestinal microbiota is associated with the pathogenesis of chronic pancreatitis. 
Therefore, we hypothesized that PERT exerts its effect by modifying the intestinal 
microbiota in addition to its presumed role in promoting fat and protein absorption. To 
explore the mechanism of action of PERT, we analyzed the intestinal microbiotas of two 
groups of mice treated with either pancrelipase or tap water by using 16S rRNA 
amplicon sequencing. The results revealed that the bacterial compositions of the 
pancrelipase-treated mice were significantly different from those of the control samples. 
Akkermansia muciniphila, a key beneficial bacterium in the intestinal tract, showed a 
higher relative abundance in the pancrelipase-treated samples than in the control 
samples. Lactobacillus reuteri, a widely used probiotic bacterium known to relieve 
intestinal inflammation, also showed a higher relative abundance in the 
pancrelipase-treated samples. These results suggested that PERT induces the 
colonization of beneficial bacteria, thereby contributing to the attenuation of 
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Chronic pancreatitis is a persistent inflammation of the pancreas with pathological 
findings of the infiltration of immune cells and the development of fibrosis [1]. Clinical 
courses of patients with chronic pancreatitis are characterized by acute exacerbation and 
remission phases. Repeated episodes of acute exacerbation cause reduction of the 
functional pancreatic parenchymal mass through the destruction of the acinar 
architecture, which leads to the development of fibrosis [1]. Such loss of functional 
pancreatic parenchymal mass results in impaired functions of both the exocrine and the 
endocrine pancreas. In fact, patients with advanced stages of chronic pancreatitis exhibit 
symptoms associated with pancreatic exocrine insufficiency (PEI), such as diarrhea, 
malabsorption, and steatorrhea [1]. PEI, caused by impaired secretion of pancreatic 
digestive enzymes due to loss of intact pancreatic acinar cells [1], represents one of the 
most frequent complications of chronic pancreatitis [2].  
Pancreatic enzyme replacement therapy (PERT) is widely used in the treatment of 
chronic pancreatitis patients exhibiting PEI-associated symptoms and improves fat and 
protein absorption and serum nutritional parameters in a significant population of these 
patients [3,4]. Recent clinical trials have shown that PERT results in relief and 















PERT is generally assumed to alleviate PEI-associated symptoms by restoring 
pancreatic digestive activity in the gastrointestinal tract. However, the mechanism by 
which PERT ameliorates PEI-associated symptoms is still poorly defined. 
Recent studies have highlighted the involvement of immune responses against 
intestinal microbiota in the development of chronic pancreatitis [6]. For example, the 
activation of pattern recognition receptors (i.e., Toll-like receptors and 
nucleotide-binding oligomerization-like receptors), that detect microbe-associated 
molecular patterns derived from the intestinal microbiota, have been reported to play a 
critical role in the development of experimental chronic pancreatitis [7,8]. Significant 
alterations in the intestinal microbiota in patients with chronic pancreatitis have also 
been reported [9,10]. Furthermore, changes in nutritional content within the 
gastrointestinal tract have been known to be able to alter the homeostatic colonization of 
commensal microbiota [11]. These studies suggest that nutrient mal-digestion caused by 
PEI leads to a significant alteration in the intestinal microbiota, which may further 
worsen chronic pancreatitis through the development of excessive innate immune 
responses. Therefore, we hypothesized that PERT improves PEI-associated symptoms 
in chronic pancreatitis not only by restoring pancreatic digestive activity, but also by 















treated with pancrelipase and performed 16S ribosomal RNA gene amplicon analyses of 
the microbiotas sampled from their cecum, transverse colon, and stool with an aim to 
understand the effect of PERT on intestinal microbiota. Our findings provide evidence 
supporting our hypothesis that PERT alleviates PEI-associated symptoms not only by 
improving digestive activity, but also by altering the composition of the intestinal 
microbiota in mice. 
 
2. Materials and Methods 
2.1. Mice 
We used 8–9-weeks-old male C57BL/6J mice (25.0 ± 0.5 g; SLC JAPAN, Inc., 
Shizuoka, Japan) and divided them into 2 groups: control and pancrelipase-treated 
groups. The control group was given tap water at the dose of 0.75 mL/day divided into 
3 parts for 21 days. The pancrelipase-treated group was treated with pancrelipase—a 
commercial mixture of pancreas amylase, lipase, and protease (chymotrypsin) 
(Lipacreon, EA pharma, Japan)—at a dose of 1.2 mg/day divided into 3 parts for 21 
days. After 21 days, the mice were killed, and their cecum, transverse colon, and stool 















according to the ethical guidelines of the review boards of Kindai University Faculty of 
Medicine, and the animal experiments were approved by the same review boards. 
2.2. DNA extraction and sequencing 
The frozen cecum, transverse colon, and stool samples were thawed and 
homogenized using Zirconia/Silica Beads (BioSpec Products) in a MagNALyzer 
(Roche Diagnostics). Following homogenization, DNA was extracted using the 
QIAamp DNA Stool Mini Kit and the QIAamp DNA Mini Kit according to the 
manufacturer’s instructions (Qiagen GmbH, Hilden Germany). The extracted DNA 
samples were used as the template in PCR for amplification of the variable V3–V4 16S 
rRNA gene regions with 16S Amplicon PCR Forward primer 
5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-MID-GT-CCTACGGGNG
GCWGCAG-3’ and 16S Amplicon PCR Reverse primer 
5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-MID-GT-GACTACHVG
GGTATCTAATCC-3’. 
Sequencing libraries were prepared using the ‘16S Metagenomic Sequencing 
Library Preparation: Preparing 16S Ribosomal RNA Gene Amplicons for the Illumina 
MiSeq System’ protocol [12] with the use of the Nextera XT Index Kit (Illumina). 















(Illumina, San Diego, CA, USA) device according to the manufacturer’s 
recommendations. 
2.3. Preprocessing of sequence data 
Low-quality sequence regions were trimmed from each paired-end read using 
Trimmomatic (version 0.35) (SLIDINGWINDOW:40:15, MINLEN:50) [13]. Primer 
sequences were trimmed from paired-end reads using Cutadapt (version 1.11) (-e 0.06, 
-pair-filter=both) [14]. The resulting trimmed paired-end reads were merged using 
FLASh (version 1.2.1) (-m 30, -M 271, -x 0.25) [15]. These merged reads are referred to 
as the “reads” in the rest of the manuscript. Raw sequence data were submitted to 
DDBJ/DRA under the accession number DRA006124. The reads are available from 
ftp://ftp.genome.jp/pub/db/community/microbiome_kindai. 
2.4. Generation of operational taxonomy units 
The following analyses were conducted using programs included in the 
Quantitative Insights Into Microbial Ecology (QIIME version 1.9.1) software [16], 
unless stated otherwise. The analyses used the representatives of 16S rRNA sequences 
from the Greengenes database (version 13_5) pre-clustered at 97% sequence identity 
threshold [17]. These representative sequences are referred to as the “reference 















The reads were each clustered against the reference sequences at 97% sequence 
identity threshold to form operational taxonomic units (OTUs) using 
parallel_pick_otus_uclust_ref.py. Reads that did not match with the reference sequences 
at the 97% sequence identity threshold were excluded from the analysis. A taxonomic 
classification was assigned to each OTU by referring to the taxonomy of the reference 
sequence included in the OTU. The resulting OTU table represents OTU identifiers, 
assigned taxonomic classifications, and read counts for each sample. 
2.5. Assessment of alpha diversity 
Alpha diversity, the diversity within a community, was assessed by rarefaction 
curves as well as by Shannon’s diversity index, the latter of which considers both the 
richness and evenness of the community structure [18]. Rarefaction curves were 
generated by averaging the OTU counts from 10 times of random re-sampling of reads 
at different depths with intervals of 5,000 sequences using 
parallel_multiple_rarefactions.py. For calculating Shannon’s diversity index, each set of 
reads was rarefied down to 57,762 reads (i.e., the number of reads for the smallest 
sample) using single_rarefaction.py. Statistical significances of the differences in 
Shannon’s index values between the samples were tested using Welch’s t-test (with a 
















2.6. Assessment of beta diversity 
Beta diversity, the dissimilarity between communities, was measured using the 
weighted UniFrac distance [20], which takes into account the relative abundances of 
each OTU and their phylogenetic relationships. The reference sequences corresponding 
to each OTU were first aligned against a template alignment provided by QIIME using 
PyNAST [21] implemented in align_seqs.py. The resulting alignment was then used to 
create a phylogenetic tree using FastTree [22] implemented in make_phylogeny.py. 
Each set of reads was rarefied down to 57,762 reads using single_rarefaction.py. The 
weighted UniFrac distances between samples were calculated using 
parallel_beta_diversity.py, together with the phylogenetic tree and the rarefied set of 
reads. 
2.7. Identification of over-/under-represented bacterial taxa  
To identify bacterial taxa that are differentially abundant (i.e., either over- or 
under-represented) in a set of samples relative to another set of samples, we first 
grouped OTUs at the species level according to their assigned taxa and generated a 
taxonomy table, which records the read counts for each taxon across samples, using 















taxonomic levels were grouped at the lowest level of taxonomy that they received. 
Bacterial taxa with the assignment of less than 10 reads were omitted from analysis 
using filter_otus_from_otu_table.py. Statistical significance of the difference in the 
relative abundance of a taxon between groups of samples (i.e., differential abundance 
between control vs. pancrelipase-treated samples) was assessed using the DESeq2 
negative binomial Wald test [23] implemented in differential_abundance.py. False 
discovery rate (q-value) was controlled at 0.1 based on the obtained p-values with the 
use of the Benjamini-Hochberg correction as implemented in DESeq2. For each 
bacterial taxon showing a significant difference in its relative abundance between two 
sample groups (i.e., q-value < 0.1), we further examined the sample group showing the 
higher average relative abundance. If one or more of the samples in this group contained 
no reads, we did not consider the taxon over- or under-represented. 
 
3. Results 
3.1. Generation of OTUs 
After quality control, we obtained a total of 5,167,710 merged reads (Table S1). Of 
these, 3,572,866 reads (69.13%) matched with reference sequences in the Greengenes 
database and formed 2,692 OTUs (corresponding to 31 orders, 54 families, 62 genera, 
















3.2. Pancrelipase treatment did not induce significant alpha diversity changes 
There were no systematic differences in the bacterial community richness (i.e., the 
number of OTUs in a sequencing depth normalized sample) between the control and the 
pancrelipase-treated group in any of the cecum, transverse colon, and stool samples 
(Figure S1A). Furthermore, there were no statistically significant differences in 
Shannon’s diversity index between the control and pancrelipase-treated samples 
(Welch’s t-test, Figure S1B). Pancrelipase treatment thus had no considerable influence 
on the alpha diversity of the tested intestinal microbiotas. 
3.3. Pancrelipase treatment induced alterations in bacterial community composition 
The bacterial composition of the pancrelipase-treated samples at the phylum level 
were clearly different from those of the control samples (Figure 1). A major difference 
was the increased relative abundances of Verrucomicrobia in the pancrelipase-treated 
samples. This phylum showed extensive increase in the pancrelipase-treated samples 
(control vs. pancrelipase, 0.13% vs. 7.58% on average). All the OTUs assigned to 
Verrucomicrobia corresponded to Akkermansia muciniphila. Another subtle difference 
was the lower Firmicutes to Bacteroidetes ratio in the transverse colon samples 















significant (Welch’s t-test, p = 0.0623). Principal coordinate analysis was further used to 
visualize compositional differences at a finer scale (i.e., at the OTU level) based on the 
weighted UniFrac distance (Figure 2). The resulting three-dimensional plot showed that 
the spatial distribution of the pancrelipase-treated samples was distinct from that of the 
control samples. 
3.4. Bacterial taxa showing significant changes in their relative abundances 
By re-grouping the 2,692 OTUs according to their taxonomic classifications, we 
obtained a taxonomy table recording read counts for 106 bacterial taxa for each samples. 
Of these, 51 bacterial taxa represented by less than 10 reads were excluded from the 
analysis. Comparison between the control and pancrelipase-treated samples revealed 17 
instances that had satisfied our criteria (see Materials and Methods) (Figure 3). In eight 
of these instances, the bacterial taxa were over-represented (i.e., higher relative 
abundance) in the pancrelipase-treated samples. These corresponded to Akkermansia 
muciniphila (cecum, transverse colon, and stool), Alcaligenaceae Sutterella (transverse 
colon), Lactobacillus reuteri (cecum), Clostridiaceae Clostridium (transverse colon), 
and Erysipelotrichaceae Coprobacillus (cecum and stool). In the remaining nine 
instances, the bacterial taxa were under-represented (i.e., lower relative abundance) in 















Desulfovibrionales Desulfovibrionaceae (transverse colon), Desulfovibrionaceae 
Desulfovibrio (transverse colon), Desulfovibrionaceae Bilophila (transverse colon, 
stool), Clostridales Lachnospiraceae (transverse colon and stool), Lachnospiraceae 
Dorea (transverse colon and stool) and Clostridiales Mogibacteriaceae (transverse 
colon). Collectively, these results suggested that pancrelipase treatment induced a 
statistically significant compositional shift in the mouse intestinal microbiota. 
 
4. Discussion 
PERT has been established as an effective treatment for PEI in chronic pancreatitis. 
However, the mechanism by which PERT ameliorates PEI-associated symptoms is still 
poorly defined. We hypothesized that PERT exerts its effect by modifying the intestinal 
microbiota, and showed that there were significant differences in the compositions of 
mouse intestinal microbiotas between pancrelipase-treated and control samples. 
Of the significant differences in the relative abundances of bacterial taxa between 
the pancrelipase-treated and control samples, the difference in the relative abundance of 
Akkermansia muciniphila (belonging to Verrucomicrobia) was the most striking. Indeed, 
the average relative abundance of A. muciniphila was 58-fold higher in the 















for chronic pancreatitis is alcohol drinking, which impairs intestinal barrier function, 
followed by translocation of intestinal bacteria [24]. A. muciniphila is known to degrade 
intestinal mucin into propionic and acetic acids, which promote beneficial microbe 
interactions in the intestinal tract [25]. In line with this, Garnder et al. previously reported 
that ethanol-induced intestinal barrier dysfunction is associated with a prominent decline 
of A. muciniphila [26]. Furthermore, supplementation of A. muciniphila was reported to 
enhance intestinal barrier function by promoting mucus thickness and tight junction 
protein expression [26]. Therefore, it is possible that pancrelipase attenuates 
PEI-associated symptoms by inducing colonization of A. muciniphila, followed by 
normalization of intestinal barrier function. However, it should be noted that whether 
pancrelipase treatment induces the colonization of this bacterium in chronic pancreatitis 
patients and beneficial effects remains to be determined. 
Four other bacteria were also over-represented in the pancrelipase-treated samples. 
One of these bacteria was Lactobacillus reuteri, a well-known probiotic bacterium. In 
fact, L. reuteri has been proven to relieve intestinal inflammation by converting 
L-histidine to histamine, which suppresses the host immune system by activating the H2 
receptor [27]. The ability of L. reuteri to prevent or alleviate colitis in mice has also 















reuteri contributes to the maintenance of intestinal immune homeostasis. Alcaligenaceae 
Sutterella, Clostridiaceae Clostridium, and Erysipelotrichaceae Coprobacillus also 
showed elevated relative abundances in the pancrelipase-treated samples, but the effect 
of colonization of these bacteria on host intestinal functions has not been clarified 
[30,31]. With regard to Clostridiaceae Clostridium, the genus contains both 
pro-inflammatory bacteria (Clostridium difficile [32]) and anti-inflammatory bacteria 
(e.g., Clostridium butyricum MIYARI 588 [33]). Together, these results indicated that A. 
muciniphila, with its ability to promote intestinal barrier function, and L. reuteri, with 
its ability to regulate inflammation, showed increased relative abundances in the colon 
and stool samples of the pancrelipase-treated mice. The colonization of such beneficial 
bacteria induced by pancrelipase treatment may partially explain the mechanisms by 
which PERT attenuates PEI-associated symptoms.  
We also identified six bacterial taxa under-represented in the pancrelipase-treated 
mice. Species belonging to the Bilophila and Desulfovibrio genera of the family 
Desulfovibrionaceae might have colitogenic functions, since they produce hydrogen 
sulfide, which promotes intestinal inflammation in rats when administered at amounts 
exceeding the capacity of colonocytes to detoxify it [34,35,36]. Lachnospiraceae Dorea 















members of the Lachnospiraceae family are known to produce butyric acid, which 
promotes intestinal epithelial barrier function [37]. Clostridiales Mogibacteriaceae also 
showed decreased relative abundances in the pancrelipase-treated mice, but the effect of 
colonization of these bacteria on host intestinal functions has not been clarified. 
A few studies have previously investigated the composition of intestinal 
microbiotas in patients with chronic pancreatitis or in model mice [9,38,39]. Jandhyala 
et al. observed significant decreases in the abundances of Faecalibacterium prausnitzii 
and Ruminococcus bromii and an increase in the Firmicutes to Bacteroidetes ratio in the 
intestinal microbiomes of chronic pancreatitis patients compared with that in healthy 
subjects. However, in our study, we could not find any significant pancrelipase-induced 
changes in these species or in the Firmicutes to Bacteroidetes ratio between the two 
groups of mice. Helicobacter pylori is a suspected pathogen of autoimmune pancreatitis 
(i.e., a rare form of chronic pancreatitis) [40]. In our study, the relative abundance of H. 
pylori was found to be very low (< 0.0035%) in the intestinal microbiotas of the mice 
and showed no significant changes upon pancrelipase treatment.  
Furthermore, several previous studies using chronic pancreatitis model mice have 
reported increases and decreases in the relative abundance of several bacterial taxa in 















taxa did not show any significant changes in their relative abundance upon pancrelipase 
treatment in our study, except for Lactobacillus and Lachnospiraceae. These bacteria 
have been previously reported to show decreased relative abundances in chronic 
pancreatitis model mice; however, the relative abundance of Lactobacillus reuteri was 
over-represented in the cecum samples of the pancrelipase-treated mice and that of 
Lachnospiraceae was under-represented in the transverse colon and stool samples of the 
pancrelipase-treated mice. Overall, the administration of pancrelipase did not induce 
microbial changes akin to those observed in chronic pancreatitis patients or its model 
mice, with the sole exception of the under-representation of Lachnospiraceae. 
Future studies on intestinal microbiotas derived from chronic pancreatitis model 
mice and patients with or without PEI need to be conducted to better understand the 
mechanism by which pancrelipase ameliorates the symptoms of chronic pancreatitis. 
To the best of our knowledge, our study is the first to reveal that oral 
supplementation of pancrelipase significantly alters the intestinal microbiota in mice. 
Our findings supports the idea that pancrelipase exerts its effect in PERT by modifying 
the gut microbiota, in addition to its presumed effect of improving the nutritional state 
of patients. Furthermore, the fact that the relative abundances of A. muciniphila and L. 















intestinal barrier—increased upon pancrelipase administration in the intestinal 
microbiota of the mice suggests that new possibilities for the treatment of chronic 
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Figure 1. Relative abundances of different bacterial taxa at the phylum level. 
Figure 2. Comparison of bacterial communities across samples. (A) OTU-level 
comparisons were performed for all control (blue) and pancrelipase-treated (red) 
samples by using principal coordinate analysis based on the weighted UniFrac distance. 
Results for the cecum (B), transverse colon (C), and stool (D) samples were plotted 
separately for better visualization. 
Figure 3. Bacterial taxa showing significantly different relative abundances between the 
control and pancrelipase-treated samples collected from the cecum (C), transverse colon 
(T), or stool (S). Relative abundances in the control and pancrelipase-treated samples 
are represented by blue and red bars, respectively. 
 
Supplementary data 
Table S1. Number of reads in samples at different steps of analyses. 
Figure S1. Comparison of alpha diversity across samples. (A) Rarefaction curves for 
the number of OTUs for samples from the control and pancrelipase-treated mice. (B) 
Shannon’s diversity index values for samples from the control (Ctrl, blue) and 
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 Oral supplementation of pancrelipase alters composition of intestinal microbiota. 
 Over-represented taxa include bacteria promoting intestinal homeostasis. 
 Akkermansia muciniphila and Lactobacillus reuteri are over-represented. 
 Pro-inflammatory bacteria is inhibited by supplementation of pancrelipase. 
 Pancrelipase may help treat chronic pancreatitis by altering intestinal microbiota. 
 
